References

  1. Pal SK, Gupta R, Somlo G et l. Lack of survival benefit in metastatic breast cancer with newer chemotherapy agents: The City of Hope cancer experience. J Clin Oncol.2008;26:s20. PubMed | Google Scholar

  2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.Science.1987;235:177-82. PubMed | Google Scholar

  3. Slamon DJ, Godolphin W, Jones LA et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989 May 12;244(4905):707-12. PubMed | Google Scholar

  4. Force T, Krause DS, Van Etten. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007 May;7(5):332-44. PubMed | Google Scholar

  5. Slamon et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15;344(11):783-92. PubMed | Google Scholar

  6. Marty M et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2- metastatic breast cancer as first line treatment: the M77001 study group. J Clin Oncol. 2005 Jul 1;23(19):4265-74. PubMed | Google Scholar

  7. Andersson M, Lidbrink E, Bjerre K et al. Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: The HERNATA study. J Clin Oncol. 2011 Jan 20;29(3):264-71. PubMed | Google Scholar

  8. Baselga J, Cortés J, Kim SB et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012 Jan 12;366(2):109-19. PubMed | Google Scholar

  9. Lewis Phillips GD, Li G, Dugger DL et al. Targeting HER2-positive breast cancer with trastuzumab- DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008 Nov 15;68(22):9280-90. PubMed | Google Scholar

  10. Hurvitz SA, Dirix L, Kocsis J et al. Trastuzumab emtansine (T-DM1) versus trastuzumab _ docetaxel in previously untreated HER2-positive metastatic breast cancer (MBC): Primary results of a randomized, multicenter, open-label phase II study (TDM4450g/BO21976) (abstract 5.001). Presented at the ESMO-ECCO European Multidisciplinary Cancer Congress, Stockholm, Sweden, September 23?27, 2011. Google Scholar

  11. ClinicalTrials.gov. A Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab/Pertuzumab Placebo Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer (MARIANNE). Available at http://ClinicalTrials.gov/ct2/show/ NCT01120184, accessed August 16, 20. Google Scholar

&